A Dual-domain Engineered Antibody for Efficient HBV Suppression and Immune Responses Restoration

Chronic hepatitis B (CHB) remains a major public health concern because of the inefficiency of currently approved therapies in clearing the hepatitis B surface antigen (HBsAg). Antibody-based regimens have demonstrated potency regarding virus neutralization and HBsAg clearance. However, high dosages or frequent dosing are required for virologic control. In this study, a dual-domain-engineered anti-hepatitis B virus (HBV) therapeutic antibody 73-DY is developed that exhibits significantly improved efficacy regarding both serum and intrahepatic viral clearance. In HBV-tolerant mice, administration of a single dose of 73-DY at 2 mg kg(-1) is sufficient to reduce serum HBsAg by over 3 log(10) IU mL(-1) and suppress HBsAg to < 100 IU mL(-1) for two weeks, demonstrating a dose-lowering advantage of at least tenfold. Furthermore, 10 mg kg(-1) of 73-DY sustainably suppressed serum viral levels to undetectable levels for approximate to 2 weeks. Molecular analyses indicate that the improved efficacy exhibited by 73-DY is attributable to the synergy between fragment antigen binding (Fab) and fragment crystallizable (Fc) engineering, which conferred sustained viral suppression and robust viral eradication, respectively. Long-term immunotherapy with reverse chimeric 73-DY facilitated the restoration of anti-HBV immune responses. This study provides a foundation for the development of next-generation antibody-based CHB therapies.